

## Stemline Therapeutics Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 09-Jul-2013

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 9

    Phase 2 Clinical..... 10

    Discovery..... 19

[Return to Table of Contents](#)

# Stemline Therapeutics Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Stemline Therapeutics Inc
<b>Parent Company Name</b>	Stemline Therapeutics Inc
<b>Website</b>	http://www.stemline.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	13
<b>Number of Inactive Drugs</b>	2
<b>Number of Patents as Owner</b>	5
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	4
<b>Key Indications</b>	Cancer,Acute myelogenous leukemia,Bladder tumor,Chronic myelocytic leukemia,Glioma,Hematological neoplasm,Myelodysplastic syndrome,Neoplasm,Solid tumor,Myeloid leukemia
<b>Key Target-based Actions</b>	IL-3 receptor modulator,CDw123 modulator,Frizzled receptor modulator,Glypican-3 modulator,Notch receptor modulator,Prominin 1 modulator,Smoothed receptor modulator,Tie 1 tyrosine kinase receptor modulator,CDw123 antagonist
<b>Key Technologies</b>	Biological therapeutic,Parenteral formulation unspecified,Monoclonal antibody,Small molecule therapeutic,Monoclonal antibody conjugated,Antibody conjugated,Imaging

## COMPANY PROFILE

### SUMMARY

Stemline Therapeutics Inc is a clinical stage biopharmaceutical company that develops oncology compounds directed at cancer stem cell targets and tumor bulks.

### FINANCIAL

In July 2013, the company was added to Russell 3000 Index.

In May 2013, the company planned to raise \$60 million gross proceeds from an underwritten public offering of 4,137,931 shares of its common stock at \$14.50 per share. The underwriters were granted a 30-day option to buy up to 620,689 additional shares of common stock. Later that month, the offering was closed. Later that month, the underwriters exercised in full their option to purchase an additional 620,689 shares of common stock. At that time, the total gross proceeds were expected to be approximately \$69,000,000 and the closing of the option to purchase additional shares was expected to occur on or about May 28, 2013.

In January 2013, the company was to raise gross proceeds of \$33,176,440, through an IPO of 3,317,644 shares of common stock priced at \$10 each. Underwriters were granted a 45-day option to purchase additional shares up to 497,647 shares of common stock to cover over-allotments. The offering was expected to close on January 31, 2013. At that time, shares were expected to be traded on the NASDAQ market on January 29, 2013. In January 2013, underwriters exercised in full their over-allotment option increasing gross proceeds from the offering to \$38,152,910; later that month, the offering was closed. Later in January 2013, the company began trading on the NASDAQ stock market.

In April 2012, the company had filed a registration statement with the SEC for a proposed IPO of its common stock.

In April 2008, Stemline raised \$12.5 million from a financing round.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	13	2	15
Hematological disease	2	2	4
Genitourinary disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	11
No Development Reported	2

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	0	0	1	0	1
Drug - Development Services	0	0	1	0	1
Technology - Target Validation	0	0	1	0	1

[Return to Table of Contents](#)



## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	0	3
Hematological disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 1	0	2
Phase not specified	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Hematological disease	1	0	1
Neoplasm	5	0	5

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)





## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### SL-401

#### SL-401 SNAPSHOT

<b>Drug Name</b>	SL-401
<b>Key Synonyms</b>	
<b>Originator Company</b>	Duke University
<b>Active Companies</b>	Stemline Therapeutics Inc
<b>Inactive Companies</b>	Duke University;Wake Forest University;Pharmacia Corp
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Chronic myelocytic leukemia;Acute myelogenous leukemia;Myelodysplastic syndrome;Neoplasm;Cancer
<b>Target-based Actions</b>	IL-3 receptor modulator;CDw123 modulator
<b>Other Actions</b>	Immunotoxin;Anticancer;Protein synthesis inhibitor
<b>Technologies</b>	Protein conjugated;Intravenous formulation;Infusion;Biological therapeutic;Protein fusion;Protein recombinant;Toxin
<b>Last Change Date</b>	08-Jul-2013

#### SL-401 DEVELOPMENT PROFILE

##### SUMMARY

Stemline Therapeutics, under license from Duke University, is developing SL-401, a biological conjugate consisting of IL-3 linked to diphtheria toxin that targets ILR-3-alpha on cancer stem cells, for the potential treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) ,. The company is also investigating SL-401 for the potential treatment of cancer including Hodgkin's lymphoma (HL) and multiple myeloma (MM),. By November 2009, Stemline was exploring the drug in phase I/II trials for AML and MDS. By February 2011, a phase I/II trial in advanced stage AML was completed and the company was 'poised' for phase III studies. In December 2011, clinical development for CML was ongoing and development was ongoing for MDL. In June 2013, data from a phase I/II BPDCN trial were presented. In January 2013, the company was planning to initiate a pivotal phase IIb trial in BPDCN patients. In December 2012, a phase IIb trial in patients with third line AML, and also trials in earlier lines of AML and other interleukin-3 receptor-expressing malignancies were being planned ; in January 2013, the company was planning to initiate a clinical trial for advanced AML that would enable registration of the drug. In April 2013, preclinical data were presented in MM.

Stemline is investigating the IL-3 receptor modulators SL-501, SL-101 and SL-102 for hematological cancers.

[Return to Table of Contents](#)



## SL-401 DEVELOPMENT STATUS

### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Acute myelogenous leukemia	US	Phase 2 Clinical	30-Nov-2009
Stemline Therapeutics Inc	Myelodysplastic syndrome	US	Phase 2 Clinical	30-Nov-2009
Stemline Therapeutics Inc	Neoplasm	US	Phase 2 Clinical	03-Jun-2013
Stemline Therapeutics Inc	Chronic myelocytic leukemia	US	Clinical	12-Dec-2011
Stemline Therapeutics Inc	Cancer	US	Discovery	11-Dec-2011
Duke University	Acute myelogenous leukemia	US	Discontinued	07-Mar-2007
Pharmacia Corp	Myeloid leukemia	US	No Development Reported	16-Apr-2003
Wake Forest University	Acute myelogenous leukemia	US	No Development Reported	30-Dec-2011
Wake Forest University	Myeloid leukemia	Canada	No Development Reported	30-Dec-2011
Wake Forest University	Myeloid leukemia	US	No Development Reported	30-Dec-2011

### SL-401 DRUG NAMES

Names	Type
DT388IL-3	Research Code
SL-401	Research Code

### SL-401 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Acute myelogenous leukemia											
0	0	0	0	0	0	0	3	0	0	0	3
Myelodysplastic syndrome											
0	0	0	0	0	0	0	1	0	0	0	1
Chronic myelocytic leukemia											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

## Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	3	0	0	0	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## SL-401 DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart




[Return to Table of Contents](#)

### Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Stemline Therapeutics Inc	0	0	2	0	2
Duke University	1	0	0	0	1
Pfizer Inc	0	0	1	0	1
University of Texas System	1	0	0	0	1
Wake Forest University	1	0	0	0	1

### Deals by Type Chart



### Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Early Research/Development	2	0	2
Drug - Development Services	1	0	1

[Return to Table of Contents](#)

## SL-701

### SL-701 SNAPSHOT

Drug Name	SL-701
Key Synonyms	
Originator Company	University of Pittsburgh
Active Companies	Stemline Therapeutics Inc
Inactive Companies	University of Pittsburgh
Highest Status	Phase 2 Clinical
Active Indications	Glioma
Target-based Actions	
Other Actions	Anticancer;Therapeutic vaccine
Technologies	Systemic formulation unspecified;Biological therapeutic;Peptide;Adult stem cell therapy
Last Change Date	08-Jan-2013

### SL-701 DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics, under license from the University of Pittsburgh, is developing SL-701, as a peptide and dendritic cell vaccine directed to multiple defined epitopes on tumor bulk and cancer stem cells (CSCs), for the potential treatment of recurrent malignant glioma. By February 2011, the vaccine had completed a phase I/II trial in recurrent malignant glioma ; in September 2012, the vaccine was still listed as being in phase I/II trial. By February 2011, the drug was poised for phase II/III trials. In January 2013, a late stage trial in pediatric patients with advanced brain cancer was planned.

### SL-701 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Glioma	US	Phase 2 Clinical	23-Feb-2011
University of Pittsburgh	Glioma	US	Discontinued	23-Feb-2011

### SL-701 DRUG NAMES

Names	Type
SL-701	

[Return to Table of Contents](#)



## SL-701 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Glioma											
0	0	0	0	0	0	0	1	0	2	0	3

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	2	0	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

SL-701 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
University of Pittsburgh	2	0	0	0	2
Stemline Therapeutics Inc	0	0	1	0	1
US Government	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Funding	1	0	1



PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Stemline Therapeutics Inc	1	0	1
University of Pittsburgh	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1

[Return to Table of Contents](#)

## SL-201

### SL-201 SNAPSHOT

Drug Name	SL-201
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Anticancer;Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	10-Mar-2011

### SL-201 DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating a small molecule cell survival inhibitor SL-201, which targets T-201, for the potential treatment of hematological and solid tumors. In March 2007, IND-enabling studies were underway. In March 2011, in vitro efficacy studies were underway.

The company was investigating SL-202, a cell survival inhibitor, for the potential treatment of hematological and solid tumors. In March 2007, IND-enabling studies were underway ; however, by March 2011, the drug was no longer listed on the company's pipeline.

### SL-201 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	08-Mar-2007

[Return to Table of Contents](#)



**SL-201 DRUG NAMES**

Names	Type
SL-202	Research Code
SL-201	Research Code
cell survival inhibitors (cancer), Stemline	

[Return to Table of Contents](#)

## SL-101

### SL-101 SNAPSHOT

Drug Name	SL-101
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hematological neoplasm
Target-based Actions	IL-3 receptor modulator;CDw123 modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody conjugated;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	10-Dec-2012

### SL-101 DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating SL-101, a monoclonal antibody conjugated to a truncated *Pseudomonas* endotoxin that targets the IL-3 receptor alpha chain (CD123) on cancer stem cells, for the potential treatment of hematological cancers. In March 2007, preclinical studies were underway; in March 2011, the drug was in in vitro efficacy studies ; in September 2012, this was still the case.

Stemline is also investigating the IL-3 receptor modulators SL-401, SL-501 and SL-102 for hematological cancers.

#### SL-101 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Hematological neoplasm	US	Discovery	29-Sep-2006

#### SL-101 DRUG NAMES

Names	Type
SL-101	Research Code

[Return to Table of Contents](#)





## SL-301

### SL-301 SNAPSHOT

Drug Name	SL-301
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Solid tumor
Target-based Actions	Notch receptor modulator
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	10-Mar-2011

### SL-301 DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating a small molecule therapeutic, SL-301, a lead from the series of notch signalling pathway modulators, for the potential treatment of solid tumors. In March 2007, preclinical studies were underway ; in March 2011, in vivo efficacy studies were underway.

The company was previously investigating SL-302, a notch signalling pathway modulator, for solid tumors ; however, by March 2011, the drug was no longer listed on the company's pipeline.

### SL-301 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Solid tumor	US	Discovery	08-Mar-2007

[Return to Table of Contents](#)



**SL-301 DRUG NAMES**

Names	Type
SL-301	Research Code
SL-302	Research Code
notch receptor modulators (cancer), Stemline	



## SL-601

### SL-601 SNAPSHOT

Drug Name	SL-601
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bladder tumor
Target-based Actions	
Other Actions	Anticancer antibody;Unspecified drug target
Technologies	Biological therapeutic;Parenteral formulation unspecified;Monoclonal antibody
Last Change Date	10-Mar-2011

### SL-601 DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating SL-601, a monoclonal antibody-based agent that targets a surface target T-601, for the potential treatment of bladder cancer. In September 2008, the drug was in preclinical development ; in March 2011, this was still the case.

### SL-601 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Bladder tumor	US	Discovery	01-Sep-2008

### SL-601 DRUG NAMES

Names	Type
SL-601	Research Code

[Return to Table of Contents](#)



## mAb based glypican-3 modulators (cancer), Stemline Therapeutics

### mAb based glypican-3 modulators (cancer), Stemline Therapeutics SNAPSHOT

Drug Name	mAb based glypican-3 modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Glypican-3 modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Biological therapeutic;Parenteral formulation unspecified;Monoclonal antibody
Last Change Date	18-Sep-2012

### mAb based glypican-3 modulators (cancer), Stemline Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating mAb-based compounds, which target glypican-3, for the potential treatment of cancer. In March 2011, the program was listed as being in preclinical development ; in September 2012, this was still the case.

### mAb based glypican-3 modulators (cancer), Stemline Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	10-Mar-2011

### mAb based glypican-3 modulators (cancer), Stemline Therapeutics DRUG NAMES

Names	Type
mAb based glypican-3 modulators (cancer), Stemline Therapeutics	Research Code
monoclonal antibody based glypican-3 modulators (cancer), Stemline Therapeutics	

[Return to Table of Contents](#)



## small molecule therapeutics (cancer), Stemline Therapeutics

### small molecule therapeutics (cancer), Stemline Therapeutics SNAPSHOT

Drug Name	small molecule therapeutics (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Anticancer;Stem cell inhibitor
Technologies	Small molecule therapeutic
Last Change Date	18-Sep-2012

### small molecule therapeutics (cancer), Stemline Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating small molecule therapeutics which target undisclosed cancer stem cells, for the potential treatment of cancer. In March 2011, in vitro efficacy studies were underway ; in September 2012, this was still the case.

### small molecule therapeutics (cancer), Stemline Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	10-Mar-2011

### small molecule therapeutics (cancer), Stemline Therapeutics DRUG NAMES

Names	Type
small molecule therapeutics (cancer), Stemline Therapeutics	

[Return to Table of Contents](#)



## mAb based CD-133 modulators (cancer), Stemline Therapeutics

### mAb based CD-133 modulators (cancer), Stemline Therapeutics SNAPSHOT

Drug Name	mAb based CD-133 modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Prominin 1 modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Biological therapeutic;Parenteral formulation unspecified;Monoclonal antibody
Last Change Date	15-Mar-2011

### mAb based CD-133 modulators (cancer), Stemline Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating mAb-based compounds, which target CD-133, for the potential treatment of cancer. In March 2011, the program was listed as being in preclinical development.

### mAb based CD-133 modulators (cancer), Stemline Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	10-Mar-2011

### mAb based CD-133 modulators (cancer), Stemline Therapeutics DRUG NAMES

Names	Type
mAb based CD-133 modulators (cancer), Stemline Therapeutics	
monoclonal antibody based CD-133 modulators (cancer), Stemline Therapeutics	Research Code

[Return to Table of Contents](#)



## mAb based Tie-1 modulators (cancer), Stemline Therapeutics

### mAb based Tie-1 modulators (cancer), Stemline Therapeutics SNAPSHOT

Drug Name	mAb based Tie-1 modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Tie 1 tyrosine kinase receptor modulator
Other Actions	Anticancer monoclonal antibody;Anticancer protein kinase inhibitor
Technologies	Biological therapeutic;Parenteral formulation unspecified;Monoclonal antibody
Last Change Date	16-Mar-2011

### mAb based Tie-1 modulators (cancer), Stemline Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating mAb-based compounds, which target Tie-1, for the potential treatment of cancer. In March 2011, the program was listed as being in preclinical development.

### mAb based Tie-1 modulators (cancer), Stemline Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	10-Mar-2011

### mAb based Tie-1 modulators (cancer), Stemline Therapeutics DRUG NAMES

Names	Type
monoclonal antibody based Tie-1 modulators (cancer), Stemline Therapeutics	
mAb based Tie-1 modulators (cancer), Stemline Therapeutics	

[Return to Table of Contents](#)



## mAb based frz receptor modulators (cancer), Stemline Therapeutics

### mAb based frz receptor modulators (cancer), Stemline Therapeutics SNAPSHOT

Drug Name	mAb based frz receptor modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Frizzled receptor modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	18-Sep-2012

### mAb based frz receptor modulators (cancer), Stemline Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating mAb-based compounds, which target frizzled (frz) receptor, for the potential treatment of cancer. In March 2011, the program was listed as being in preclinical development ; in September 2012, this was still the case.

### mAb based frz receptor modulators (cancer), Stemline Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	10-Mar-2011

### mAb based frz receptor modulators (cancer), Stemline Therapeutics DRUG NAMES

Names	Type
mAb based frz receptor modulators (cancer), Stemline Therapeutics	
monoclonal antibody based frizzled receptor modulators (cancer), Stemline Therapeutics	

[Return to Table of Contents](#)



## mAb based Ptc modulators (cancer), Stemline Therapeutics

### mAb based Ptc modulators (cancer), Stemline Therapeutics SNAPSHOT

Drug Name	mAb based Ptc modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Unspecified drug target;Anticancer monoclonal antibody
Technologies	Monoclonal antibody;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	16-Mar-2011

### mAb based Ptc modulators (cancer), Stemline Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating mAb-based compounds, which target Ptc, for the potential treatment of cancer. In March 2011, the program was listed as being in preclinical development.

### mAb based Ptc modulators (cancer), Stemline Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	10-Mar-2011

### mAb based Ptc modulators (cancer), Stemline Therapeutics DRUG NAMES

Names	Type
monoclonal antibody based Ptc modulators (cancer), Stemline Therapeutics	
mAb based Ptc modulators (cancer), Stemline Therapeutics	

[Return to Table of Contents](#)

## mAb based Smo modulators (cancer), Stemline Therapeutics

### mAb based Smo modulators (cancer), Stemline Therapeutics SNAPSHOT

Drug Name	mAb based Smo modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Smoothened receptor modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	16-Mar-2011

### mAb based Smo modulators (cancer), Stemline Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Stemline Therapeutics is investigating mAb-based compounds, which target Smo receptor, for the potential treatment of cancer. In March 2011, the program was listed as being in preclinical development.

### mAb based Smo modulators (cancer), Stemline Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Stemline Therapeutics Inc	Cancer	US	Discovery	10-Mar-2011

### mAb based Smo modulators (cancer), Stemline Therapeutics DRUG NAMES

Names	Type
mAb based Smo modulators (cancer), Stemline Therapeutics	
monoclonal antibody based Smo modulators (cancer), Stemline Therapeutics	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

